skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Recent months have seen a remarkable convergence of initiatives to foster greater European cooperation in market access. On the one hand, the EU has been promoting measures to expedite the launch of new medicines (eg adaptive pathways) and facilitate joint activity in health technology assessment. On the other hand, concerns over the pricing of some new drugs – most notably Gilead’s Sovaldi (sofosbuvir) – have prompted national governments to seek new alliances in order to help control the cost of innovative medicines. Whilst international collaboration in market access has undeniable attractions, it’s important to understand the recent changes thoroughly, especially in terms of the challenges such collaborations are likely to present in practice.


Our latest report provides an in-depth analysis into the recent key developments in the pharmaceutical market access environment and today, we are offering you a complimentary extract of this exclusive report.


This sample extract will provide you with an overview of our latest report ‘Key Trends in European Market Access’ which reviews in-depth the key developments in the pharmaceutical market access environment


  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート



    Topics Coronavirus Vaccines

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...


    By Dustin Phan


    Topics Coronavirus Clinical Trials

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート

    mHealth and Research in Oncology

    The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit.